Veteran chairman Rick Holliday-Smith is back in the headlines on Monday, having appointed former Challenger boss Dominic Stevens to run ASX Limited.
But he is also readying his pitch for a new initial public offering; anticancer drug company QBiotics.
QBiotics is in the market for up to $12.5 million which, if successful, would see it list with a $118.1 million market capitalisation in September.
Holliday-Smith lines up as chairman, adding QBiotics to list list of directorships which include ASX, Cochlear and Servcorp.
Holliday-Smith told potential investors that he was approached to chair the company late last year and decided it was best to wait for regulatory approvals before listing.
QBiotics is developing anticancer products for human and veterinary markets.
It says the company's lead anticancer drug, called EBC-46, has proven to be "efficacious against a range of spontaneous tumours".
Axstra Capital is running the IPO as offer manager, while Thomson Geer is doing the legal work.
